MicroRNA-145 suppresses cell proliferation, invasion and migration in pancreatic cancer cells by targeting NEDD9

Han,Tong; Yi,Xiao‑Ping; Liu,Bo; Ke,Mu‑Jing; Li,Yi‑Xiong

doi:10.3892/mmr.2015.3294

MicroRNA-145 suppresses cell proliferation, invasion and migration in pancreatic cancer cells by targeting NEDD9

Authors:
- Tong Han
- Xiao‑Ping Yi
- Bo Liu
- Mu‑Jing Ke
- Yi‑Xiong Li
View Affiliations

Affiliations: Department of General Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China, Department of Radiology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China, State Key Laboratory of Medical Genetics, Central South University, Changsha, Hunan 410008, P.R. China
Published online on: February 3, 2015 https://doi.org/10.3892/mmr.2015.3294
Pages: 4115-4120
Copyright: © Han et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs) represent a class of small non‑coding RNAs regulating gene expression by inducing the degradation of RNA or interfering with translation. Aberrant miRNA expression has been described in several types of cancer in humans. In the present study, it was demonstrated that miR‑145 is downregulated in pancreatic cancer tissues and the Panc‑1 cell line. Restoration of miR‑145 inhibited cell proliferation, invasion and migration in Panc‑1 cells. Neural precursor cell expressed, developmentally down‑regulated 9 (NEDD9) has been identified as a novel potential miR‑145 target using bioinformatics. Using luciferase reporter constructs, it was observed that the NEDD9 3'‑untranslated region is the location of the direct binding site for miR‑145. Additionally, it was identified that miR‑145 is inversely correlated with NEDD9 expression in pancreatic cancer tissues and that restoration of miR‑145 in Panc‑1 cells reduced NEDD9 mRNA and protein expression accompanied by inhibition of cell proliferation, invasion and migration. In conclusion, these findings indicate that miR‑145 may be an effective target for pancreatic cancer therapy.

View Figures

View References

1	Muniraj T, Jamidar PA and Aslanian HR: Pancreatic cancer: a comprehensive review and update. Dis Mon. 59:368–402. 2013. View Article : Google Scholar : PubMed/NCBI
2	Bartel DP: MicroRNAs: genomics, biogenesis, mechanism and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
3	Xi JJ: MicroRNAs in Cancer. Cancer Treat Res. 158:119–137. 2013. View Article : Google Scholar : PubMed/NCBI
4	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
5	Zhang B, Pan X, Cobb GP and Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12. 2007. View Article : Google Scholar
6	Wang Z: Advances with microRNAs in tumorigenesis and cancer therapy. Curr Pharm Des. 20:52452014. View Article : Google Scholar : PubMed/NCBI
7	Xing AY, Wang B, Shi DB, et al: Deregulated expression of miR-145 in manifold human cancer cells. Exp Mol Pathol. 95:91–97. 2013. View Article : Google Scholar : PubMed/NCBI
8	Wu H, Xiao Z, Wang K, Liu W and Hao Q: MiR-145 is down-regulated in human ovarian cancer and modulates cell growth and invasion by targeting p70S6K1 and MUC1. Biochem Biophys Res Commun. 441:693–700. 2013. View Article : Google Scholar : PubMed/NCBI
9	Fuse M, Nohata N, Kojima S, et al: Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. Int J Oncol. 38:1093–1101. 2011.PubMed/NCBI
10	Chiyomaru T, Enokida H, Tatarano S, et al: miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer. 102:883–891. 2010. View Article : Google Scholar : PubMed/NCBI
11	Cho WC, Chow AS and Au JS: Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. Eur J Cancer. 45:2197–2206. 2009. View Article : Google Scholar : PubMed/NCBI
12	Wang S, Bian C, Yang Z, et al: miR-145 inhibits breast cancer cell growth through RTKN. Int J Oncol. 34:1461–1466. 2009.PubMed/NCBI
13	Mees ST, Schleicher C, Mardin WA, Senninger N, Colombo-Benkmann M and Haier J: Analyzing miRNAs in ductal adenocarcinomas of the pancreas. J Surg Res. 169:241–246. 2011. View Article : Google Scholar
14	Papaconstantinou IG, Manta A, Gazouli M, et al: Expression of microRNAs in patients with pancreatic cancer and its prognostic significance. Pancreas. 42:67–71. 2013. View Article : Google Scholar
15	O’Neill GM, Seo S, Serebriiskii IG, Lessin SR and Golemis EA: A new central scaffold for metastasis: parsing HEF1/Cas-L/NEDD9. Cancer Res. 67:8975–8979. 2007. View Article : Google Scholar
16	Izumchenko E, Singh MK, Plotnikova OV, et al: NEDD9 promotes oncogenic signaling in mammary tumor development. Cancer Res. 69:7198–7206. 2009. View Article : Google Scholar : PubMed/NCBI
17	Lai EC: Micro RNAs are complementary to 3′ UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet. 30:363–364. 2002. View Article : Google Scholar : PubMed/NCBI
18	Iorio MV and Croce CM: MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol. 27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
19	Szafranska AE, Davison TS, John J, et al: MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene. 26:4442–4452. 2007. View Article : Google Scholar : PubMed/NCBI
20	Lee EJ, Gusev Y, Jiang J, et al: Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer. 120:1046–1054. 2007. View Article : Google Scholar
21	Seo S, Ichikawa M and Kurokawa M: Structure and function of cas-L and integrin-mediated signaling. Crit Rev Immunol. 26:391–406. 2006. View Article : Google Scholar
22	Singh MK, Izumchenko E, Klein-Szanto AJ, Egleston BL, Wolfson M and Golemis EA: Enhanced genetic instability and dasatinib sensitivity in mammary tumor cells lacking NEDD9. Cancer Res. 70:8907–8916. 2010. View Article : Google Scholar : PubMed/NCBI
23	Chang JX, Gao F, Zhao GQ and Zhang GJ: Expression and clinical significance of NEDD9 in lung tissues. Med Oncol. 29:2654–2660. 2012. View Article : Google Scholar : PubMed/NCBI
24	Kim M, Gans JD, Nogueira C, et al: Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell. 125:1269–1281. 2006. View Article : Google Scholar : PubMed/NCBI
25	Speranza MC, Frattini V, Pisati F, et al: NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma. Oncotarget. 3:723–734. 2012.PubMed/NCBI
26	Xue YZ, Sheng YY, Liu ZL, et al: Expression of NEDD9 in pancreatic ductal adenocarcinoma and its clinical significance. Tumour Biol. 34:895–899. 2013. View Article : Google Scholar